<DOC>
	<DOC>NCT01153360</DOC>
	<brief_summary>This study is planned to medicate oral T3(Liothyronine)to the patients who are planned to have OPCAB(off- pump coronary bypass graft surgery. The aim of this study was to assess the effects of oral triiodothyronine (T3) therapy on postoperative thyroid hormone concentrations, hemodynamic variables and outcomes in patients undergoing OPCAB in a randomized, controlled trial.</brief_summary>
	<brief_title>Peri-operative Oral Triiodothyronine Replacement Therapy to Decrease the Risk of Transient Atrial Fibrillation After Off-pump Coronary Artery Bypass Surgery</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Euthyroid Sick Syndromes</mesh_term>
	<criteria>Patients who are undergoing Offpump coronary artery bypass graft No normal sinus rhythm, History of thyroid disease Abnormal thyroid hormone Renal dysfunction Hepatic dysfunction LVEF &lt;30% Recent MI Active infection 1~15</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>